NYSE:TDOC
Teladoc Health, Inc.
Teladoc Health is a leading virtual care platform delivering accessible healthcare services through digital channels to patients across multiple geographies.
Key Metrics
Investment Thesis
Bull Case
Teladoc's strong balance sheet with $781.1 million in cash and equivalents provides ample runway to fund growth initiatives and navigate the transition to profitability without immediate dilution concerns. The secular trend toward digital-first healthcare supports long-term revenue visibility, and the company's diversified service offerings mitigate reliance on any single payer model or geographic market.
Bear Case
The persistent net losses over recent years and a retained earnings deficit of $16.43 billion suggest structural profitability issues that may require significant time and capital to resolve. With cash flow from financing activities draining $551.7 million, the company faces pressure to reduce burn rates or raise additional capital, which could dilute shareholders if operational performance does not improve quickly.
About Teladoc Health, Inc.
Teladoc Health provides virtual care services through its platform, which connects patients with healthcare professionals via video visits, phone calls, and mobile app messaging. The company operates primarily in the United States, Canada, and Europe, offering primary care, behavioral health, specialty care, and nursing services to individuals, employers, and payers.
Analysis
Management Discussion
Despite generating positive operating cash flow of $294.4 million, the company reported a significant net loss of $200.3 million driven by substantial amortization of intangible assets totaling $350.8 million and high general and administrative costs of $431.9 million. Revenue growth has stalled with a slight decline from 2023 to 2025, indicating that recent strategic investments in acquisitions and technology have yet to translate into proportional top-line expansion or bottom-line recovery.
Industry Overview
The digital health industry is experiencing rapid adoption of telehealth services post-pandemic, yet consolidation and regulatory scrutiny are intensifying competition among major players like Teladoc, Amwell, and UnitedHealthcare. Payors are increasingly demanding cost containment measures that favor bundled payment models over volume-based reimbursement, challenging traditional virtual care revenue structures.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.41B | $2.60B | $2.57B | $2.53B |
| Cost of Revenue | $744.0M | $760.0M | $751.3M | $771.6M |
| Gross Profit | $1.66B | $1.84B | $1.82B | $1.76B |
| Operating Expenses | $15.32B | $2.09B | $2.84B | $2.02B |
| Operating Income | $-13.65B | $-248.6M | $-1.02B | $-263.0M |
| R&D | $333.6M | $348.5M | $307.3M | $277.9M |
| G&A | $449.9M | $464.7M | $435.5M | $431.9M |
| Stock-Based Comp | $217.9M | $201.6M | $146.0M | $80.4M |
| D&A | $256.0M | — | — | — |
| Depreciation | $11.4M | — | — | — |
| Amortization | $244.6M | $325.9M | $363.4M | $350.8M |
| Other OpEx | $14.53B | $1.28B | $2.10B | $1.31B |
| Non-Operating Income | $-10.1M | $28.9M | $27.2M | $27.4M |
| Interest Expense | — | $22.3M | $23.8M | — |
| Interest Income | — | $46.8M | $57.1M | $36.8M |
| Pre-Tax Income | $-13.66B | $-219.6M | $-993.7M | $-235.5M |
| Income Tax | $-3.8M | $760.0K | $7.6M | $-35.2M |
| Continuing Ops | $-13.66B | $-220.4M | $-1.00B | $-200.3M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-13.66B | $-220.4M | $-1.00B | $-200.3M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-13.66B | $-220.4M | $-1.00B | $-200.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.32B | $1.49B | $1.66B | $1.12B |
| Cash & Equivalents | $918.2M | $1.12B | $1.30B | $781.1M |
| Accounts Receivable | $210.6M | $217.4M | $214.1M | $192.8M |
| Inventory | $56.3M | $29.5M | $38.1M | $38.2M |
| Prepaid Expenses | $130.3M | $118.4M | $113.3M | $107.0M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $3.03B | $2.90B | $1.85B | $1.74B |
| PP&E (Net) | $29.6M | $32.0M | $29.5M | $27.0M |
| Intangibles | $1.84B | $1.68B | $1.43B | $1.30B |
| Goodwill | $1.07B | $1.07B | $283.2M | $283.2M |
| Operating Leases | $41.8M | $40.1M | $27.1M | $26.1M |
| Other LT Assets | $48.5M | $80.3M | $81.5M | $105.8M |
| Total Assets | $4.35B | $4.39B | $3.52B | $2.86B |
| Current Liabilities | $399.8M | $420.6M | $941.5M | $404.7M |
| Accounts Payable | $47.7M | $43.6M | $33.1M | $48.0M |
| Current Leases | $13.6M | $10.8M | $10.3M | $11.0M |
| Deferred Revenue | — | $95.7M | $79.3M | $62.3M |
| Taxes Payable | $3.8M | $621.0K | — | — |
| Other Current Liab | $334.7M | $269.9M | $818.8M | $283.4M |
| Long-Term Liabilities | $1.64B | $1.65B | $1.08B | $1.07B |
| LT Operating Leases | $38.0M | $42.8M | $32.1M | $34.2M |
| Other LT Liab | $1.60B | $1.59B | $1.04B | $1.02B |
| Total Liabilities | $2.04B | $2.07B | $2.03B | $1.47B |
| Shareholders' Equity | $2.31B | $2.33B | $1.49B | $1.39B |
| Retained Earnings | $-15.01B | $-15.23B | $-16.23B | $-16.43B |
| AOCI | $-42.8M | $-37.0M | $-38.4M | $-34.7M |
| Total L&E | $4.35B | $4.39B | $3.52B | $2.86B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-13.66B | $-220.4M | $-1.00B | $-200.3M |
| Non-Cash Adjustments | $13.71B | $574.3M | $1.35B | $551.0M |
| Working Capital Changes | $135.6M | $-3.9M | $-54.1M | $-56.4M |
| Cash from Operations | $189.3M | $350.0M | $293.7M | $294.4M |
| Capital Expenditures | $16.5M | $11.5M | $10.8M | $8.9M |
| Cash from Investing | $-167.7M | $-156.3M | $-124.1M | $-266.0M |
| Cash from Financing | $6.5M | $10.9M | $8.3M | $-551.7M |
| FX Effect | $-3.3M | $965.0K | $-3.3M | $6.1M |
| Net Change in Cash | $28.0M | $204.5M | $177.9M | $-523.3M |
| Beginning Cash | $893.5M | $918.2M | $1.12B | $1.30B |
| Ending Cash | $918.2M | $1.12B | $1.30B | $781.1M |
Frequently Asked Questions
How does Teladoc Health, Inc. make money?
Revenue streams include direct-to-consumer memberships for primary and behavioral health, employer-sponsored plans covering telehealth visits, payer contracts reimbursing for specific telemedicine services, and specialty programs like nursing and dermatology delivered remotely.
What are the main risks for TDOC?
Sustained profitability challenges are evident with recent net losses exceeding $200 million, raising concerns about the path to positive cash flow given operating expenses of over $2 billion. Regulatory risks remain high as healthcare pricing models shift away from fee-for-service toward value-based care, potentially impacting revenue per visit. High customer acquisition costs in a competitive digital health landscape could erode margins further if growth does not accelerate alongside efficiency improvements.
What is TDOC's competitive advantage?
The company leverages a proprietary technology stack that integrates seamlessly with electronic health records and third-party platforms, while its extensive network of licensed clinicians ensures high-quality care. Teladoc benefits from strong brand recognition in the virtual care space and has successfully diversified its service lines beyond simple telehealth consultations to include chronic disease management and behavioral health.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.